Media release detail page

Polyphor shareholders approve all motions proposed by the Board of Directors at the Annual General Meeting

EQS Group-News: Polyphor AG / Key word(s): AGMEGM

12.04.2019 / 17:45

Allschwil, Switzerland, April 12, 2019

Polyphor shareholders approve all motions proposed by the Board of Directors at the Annual General Meeting

Polyphor AG (SIX: POLN) shareholders today approved all motions put forward by the Board of Directors to the 22nd Annual General Meeting in Basel. The meeting was attended by 62 shareholders. A total of 50% of the company's voting share capital was represented.

The members of the Board of Directors, Argeris N. Karabelas, Kuno Sommer, Bernard Bollag, Silvio Inderbitzin, Jean-Pierre Obrecht, Andreas Wallnöfer and Frank T. Weber were re-elected for a further year in office. In addition, the shareholders approved the re-election of Argeris N. Karabelas as Chairman of the Board of Directors.

The shareholders also approved the total maximum amount of compensation for the Board of Directors and the total maximum amount of compensation for the members of the Executive Management for the financial year 2019. Furthermore, shareholders also approved the increase of conditional capital for employee benefit plans.

For further information please contact:

For Investors:
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67

For Media:
Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31


About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of antibiotics and immuno-oncology compounds. It has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead OMPTA, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO; in addition, Polyphor is developing a pipeline of further preclinical antibiotics based on its OMPTA platform. In addition, Polyphor is developing an immuno-oncology candidate, balixafortide (POL6326), which is starting a Phase III trial in combination with eribulin in patients with advanced breast cancer, and exploring in parallel its potential for further combinations and indications. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit

This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Additional features:

Document: Polyphor_AGM_12.4.2019

End of Corporate News

show this